Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M175,490Revenue (TTM) $M49,436Net Margin (%)13.5Altman Z-Score2.4
Enterprise Value $M186,531EPS (TTM) $2.8Operating Margin %16.7Piotroski F-Score5
P/E(ttm)28.2Beneish M-Score-2.7Pre-tax Margin (%)15.7Higher ROA y-yN
Price/Book2.410-y EBITDA Growth Rate %--Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %3.9Current Ratio1.1Lower Leverage y-yN
Price/Free Cash Flow23.0y-y EBITDA Growth Rate %71.3ROA % (ttm)5.1Higher Current Ratio y-yY
Dividend Yield %3.5PEG7.2ROE % (ttm)9.0Less Shares Outstanding y-yY
Payout Ratio %96.0Shares Outstanding M2,374ROIC % (ttm)7.6Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

NVS is held by these investors:

NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15415.2view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
    Novartis Has Bright Future Feb 01 2017 
    2 Top Health Care Dividend Stocks Jan 12 2017 
    7 Stocks With Low P/S Ratios Jan 11 2017 
    Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
    Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
    Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
    The Pharmaceutical Sector Looks Attractive Oct 12 2016 
    Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
    Novartis Is Surviving Oct 03 2016 

    More From Other Websites
    Novartis Lung Cancer Drug Combo Gets CHMP Nod Feb 24 2017
    Novartis Cancer Drug Zykadia Gets Priority Review Feb 24 2017
    Novartis wins CHMP nod for drug combo against some lung cancers Feb 24 2017
    Blog Coverage Novartis Gains Priority Review from the FDA for its Cancer Drug Zykadia as a Frontline... Feb 24 2017
    Ring the Register With These Upcoming Spinoffs Feb 24 2017
    Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs Feb 24 2017
    7:10 am Novartis AG confirms the CHMP adopted a positive opinion recommending approval of Tafinlar... Feb 24 2017
    Morningstar's 5 Favorite Foreign-Stock ETFs Feb 24 2017
    Teva Is Expected to See a Fall in Its Profit Margins in 2017 Feb 23 2017
    Medford's Seventh Sense wins narrow FDA approval for blood-collection device Feb 23 2017
    5 reasons to invest in European stocks now Feb 23 2017
    This Keeps Driving Sanofi’s Growth Feb 20 2017
    Blog Coverage Ionis Pharma Closed on its Collaboration Agreement with Novartis Following Clearance... Feb 17 2017
    Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback Feb 16 2017
    GlaxoSmithKline’s Valuation Compared to Its Peers Feb 16 2017
    Bristol-Myers: Don't Bet on a Pfizer Acquisition Feb 15 2017
    Bristol-Myers Squibb: Takeover Target? Feb 14 2017
    4Q16 Performance of GlaxoSmithKline’s Business Segments Feb 14 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)